Q-omics provides the consensus-scored KRT2 profile across patient tissues and cancer cell-line models. KRT2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, KRT2 is differentially expressed in 9, with the highest sampling consensus in BRCA. Additionally, KRT2 RNA expression shows 9,801 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, BRCA, and TGCT as cancer lineages where KRT2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRT2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRT2 survival associations across molecular data types. KRT2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRT2 RNA expression–survival associations across cancer types. High KRT2 expression shows unfavorable associations in KIRP, LGG, BRCA, UVM and THCA, but favorable associations in ESCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for KRT2 RNA expression.
This table summarizes KRT2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for KRT2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRT2 shows lower tumor expression in KICH, COAD and LUAD and higher tumor expression in BRCA, KIRC and LUSC. The BRCA box plot shows higher KRT2 RNA expression in tumor versus normal tissue (log2 FC = +0.128, t-test p < 0.001).
This table shows molecular features associated with KRT2 in patient tissues and cancer cell lines. In patient samples, KRT2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, KRT2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
